Core Insights - TScan Therapeutics, Inc. announced the acceptance of an abstract for a poster presentation at the ASGCT 28th Annual Meeting, highlighting its focus on TCR-engineered T cell therapies for cancer treatment [1][2]. Company Overview - TScan is a clinical-stage biotechnology company specializing in T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed to prevent relapse in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation, specifically through the ALLOHA™ Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets across multiple HLA types, to offer customized multiplex TCR-T therapies for various cancers, as seen in the PLEXI-T™ Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3]. Presentation Details - The poster presentation titled "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation" will take place on May 13 from 6:00 - 7:30 p.m. Central Time [2]. - The presentation will be held in the Poster Hall, Hall I2, and materials will be available on the company's website post-presentation [2].

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Pres ...

WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the ...

Core Insights - TScan Therapeutics (TCRX) is highlighted as a significant biotech company to monitor in the upcoming year due to its development of T-Cell Receptor engineered T-cells (TCR-T) aimed at treating residual disease [2]. Company Overview - TScan Therapeutics is engaged in the innovative field of T-cell therapy, focusing on engineered T-cells to address unmet medical needs in oncology [2]. Market Position - The company is part of a broader biotech landscape that includes a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks, indicating a robust analytical framework for investors [2].

分组1 - TScan Therapeutics reported a quarterly loss of $0.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, and compared to a loss of $0.21 per share a year ago, indicating a negative earnings surprise of -7.41% [1] - The company posted revenues of $0.67 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 53.59%, and this represents a significant decline from year-ago revenues of $7.21 million [2] - TScan Therapeutics shares have declined approximately 33.6% since the beginning of the year, contrasting with the S&P 500's decline of -1.8% [3] 分组2 - The earnings outlook for TScan Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.28 on revenues of $1.62 million, and for the current fiscal year at -$1.14 on revenues of $10.97 million [7] - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Another company in the same industry, Voyager Therapeutics, is expected to report a quarterly loss of $0.35 per share, reflecting a year-over-year change of -128%, with revenues anticipated to be $20.13 million, down 77.7% from the previous year [9][10]

Financial Performance - For the years ended December 31, 2024, 2023, and 2022, the company reported net losses of $127.5 million, $89.2 million, and $66.2 million, respectively, with an accumulated deficit of $375.1 million as of December 31, 2024[268]. - The company anticipates significant increases in expenses as product candidates advance through preclinical studies and clinical trials, necessitating substantial additional funding for development and commercialization efforts[280]. - The company expects its financial condition and operating results to fluctuate significantly from quarter to quarter and year to year due to various uncontrollable factors[276]. - Global economic uncertainty and financial market volatility may adversely affect the company's ability to access financing and could impact business operations[286]. - The company may need to raise additional capital through various means, including equity or debt financing, which could dilute existing stockholder ownership[284]. - Future capital requirements will depend on various factors, including the scope and progress of drug discovery and clinical development activities[282]. Research and Development - The company has incurred significant research and development expenses and continues to do so, with no products licensed for commercial sale to date[267]. - The success of the company's proprietary platform is critical for discovering and developing product candidates, which require significant investment and regulatory approval[270]. - The company acknowledges the inherent risks in biotechnology R&D and may not successfully develop a pipeline of commercially viable product candidates[347]. - The company faces significant risks in biotechnology product development, including the potential failure to demonstrate adequate efficacy or safety profiles for its product candidates[350]. - The company has limited experience in conducting clinical trials and managing manufacturing facilities, which may lead to delays[304]. Clinical Trials and Regulatory Approval - The company has initiated clinical trials for several product candidates, but revenue generation is not expected for many years[302]. - There is no guarantee that any product candidates will achieve regulatory approval, as the process is lengthy and fraught with challenges[306]. - The company may need to conduct additional clinical trials to obtain regulatory approval for its product candidates, which could delay commercialization[353]. - The FDA has cleared the T-Plex IND application, allowing the company to combine product candidates in multiplex TCR-T therapy, but safety data for each candidate is still required[331]. - Delays in obtaining regulatory approval could materially adversely impact the company's business and prospects[404]. Manufacturing and Supply Chain - Manufacturing difficulties may arise from limited experience, resource constraints, or geopolitical tensions, particularly with suppliers in China[321]. - The company relies on third-party contract manufacturers for clinical product supplies, which may affect compliance with regulatory requirements[320]. - The manufacturing process is susceptible to product loss or failure due to various logistical and operational issues, which could adversely affect patient outcomes[382]. - The company has expanded its existing cell manufacturing facility but lacks direct experience in managing such expansions, which may lead to delays in clinical trials and product quality issues[305]. Market and Competitive Landscape - The biotechnology industry is characterized by intense competition, and the company may face challenges from larger competitors with greater resources[371]. - The market opportunities for the company's product candidates may be relatively small, and estimates of the prevalence of target patient populations may be inaccurate[353]. - The company currently has no marketing and sales organization and lacks experience in marketing products, which may hinder its ability to generate product revenue[358]. Compliance and Regulatory Risks - The company must comply with extensive regulatory requirements, including safety monitoring and quality control, which could impact operational costs[420]. - The company faces ongoing regulatory obligations post-approval, which may lead to significant additional expenses and potential penalties for non-compliance[420]. - The company is subject to stringent data privacy laws, such as the California Consumer Privacy Act (CCPA), which imposes new obligations and potential penalties for noncompliance[447]. - Non-compliance with environmental, health, and safety regulations could result in fines or penalties, adversely affecting business success[456]. Cybersecurity and Data Privacy - The company has not experienced any material system failures or cybersecurity incidents, but potential disruptions could significantly impact development programs and business operations[373]. - Unauthorized disclosure of sensitive data could lead to negative publicity, legal liability, and damage to the company's reputation[374]. - The company must invest significant resources to protect against cybersecurity incidents and data breaches, which could have material adverse effects on its business[376]. Funding and Financial Strategy - The company has a loan agreement with Silicon Valley Bank for up to $52.5 million, with $32.5 million fully funded and a second tranche of $20 million available at SVB's discretion[295]. - The company may need to pursue equity or debt financing to meet capital needs, which could lead to significant dilution for existing stockholders[289]. - The company may seek orphan drug status for product candidates, which could provide financial incentives but may not guarantee market exclusivity[405]. Pricing and Reimbursement - Coverage and adequate reimbursement from government programs and private insurers are critical for the successful commercialization of products[459]. - The uncertainty surrounding third-party payer reimbursement could limit the company's ability to market its products and generate revenue[422]. - The company anticipates that adverse publicity related to engineered T cell therapies could negatively impact market acceptance of its product candidates[364].

Revenue Performance - Revenue for Q4 2024 was $0.7 million, down 90.3% from $7.2 million in Q4 2023; full-year revenue decreased to $2.8 million from $21.0 million in 2023[6]. - Collaboration and license revenue for the three months ended December 31, 2024, was $665 million, compared to $7,211 million for the same period in 2023[21]. Expenses and Losses - R&D expenses increased to $29.4 million in Q4 2024, up 31.3% from $22.4 million in Q4 2023; full-year R&D expenses rose to $107.4 million from $88.2 million[9]. - Total operating expenses increased to $37,377 million for the three months ended December 31, 2024, from $28,568 million in the prior year, representing a 30.5% increase[21]. - The net loss for Q4 2024 was $35.8 million, compared to $19.6 million in Q4 2023; full-year net loss increased to $127.5 million from $89.2 million[11]. - The net loss for the three months ended December 31, 2024, was $35,809 million, compared to a net loss of $19,613 million for the same period in 2023, indicating an increase of 82.4%[21]. - Total operating expenses for the twelve months ended December 31, 2024, were $137,637 million, up from $114,507 million in 2023, marking a 20.2% increase[21]. - The loss from operations for the twelve months ended December 31, 2024, was $134,821 million, compared to $93,458 million in 2023, indicating a significant increase of 44.3%[21]. - The company reported a net loss of $127,499 million for the twelve months ended December 31, 2024, compared to a net loss of $89,218 million in 2023, reflecting an increase of 43%[21]. Cash Position - Cash, cash equivalents, and marketable securities as of December 31, 2024, were $290.1 million, sufficient to fund operations into Q1 2027[12]. - The company closed a $30 million registered direct offering at a 37% premium, extending its cash runway[6]. Clinical Development - Seven TCR-Ts are now cleared for clinical development in the PLEXI-T Phase 1 trial, including the recently added MAGE-A4 TCR-T[7]. - TScan plans to initiate a registration trial for TSC-101 in the second half of 2025, pending regulatory feedback[7]. - The company aims to present additional data from the Phase 1 trial by the end of 2025, including two-year relapse data[7]. Recognition - TScan has been recognized as one of the Top Places to Work in Massachusetts for the third consecutive year[6].

Core Insights - TScan Therapeutics, Inc. reported significant progress in its clinical trials, particularly the ALLOHA™ Phase 1 heme trial, showing promising results in preventing relapse in patients with hematologic malignancies [2][4] - The company has successfully cleared an IND application for its seventh TCR in the PLEXI-T™ Phase 1 solid tumor program, targeting MAGE-A4 [1][4] - Financially, TScan closed a $30 million registered direct offering at a 37% premium, extending its cash runway into the first quarter of 2027 [1][4] Clinical Development - The ALLOHA trial results indicated that only 2 out of 26 patients (8%) relapsed compared to 4 out of 12 patients (33%) in the control arm, with a median time to relapse not evaluable in the treatment group [4] - TScan's lead TCR-T therapy candidates, TSC-100 and TSC-101, have shown good tolerability with no dose-limiting toxicities, and TCR-T cells have been detected over one year post-infusion [4][6] - The company plans to initiate a registration trial for TSC-101 in the second half of 2025 and expects to present additional data from the Phase 1 trial by the end of the year [11][12] Financial Performance - Revenue for Q4 2024 was $0.7 million, a decrease from $7.2 million in Q4 2023, and total revenue for the full year 2024 was $2.8 million compared to $21.0 million in 2023 [7] - R&D expenses increased to $29.4 million in Q4 2024 from $22.4 million in Q4 2023, driven by clinical study expenses and increased personnel costs [8] - The net loss for Q4 2024 was $35.8 million, compared to $19.6 million in Q4 2023, with a full-year net loss of $127.5 million compared to $89.2 million in 2023 [10][20] Cash Position and Future Outlook - As of December 31, 2024, TScan had cash, cash equivalents, and marketable securities totaling $290.1 million, which is expected to fund operations into the first quarter of 2027 [11][12] - The company has expanded its ImmunoBank to include multiple TCR-T therapy candidates, aiming to address tumor heterogeneity and resistance [6][13] - TScan has plans to file an IND application for TSC-102-A0301 in the second half of 2025 and to treat its first patient with multiplex therapy in the first half of 2025 [11][12]

Core Insights - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment [3] Group 1: Company Overview - TScan's lead TCR-T therapy candidates are aimed at treating patients with hematologic malignancies to prevent relapse after allogeneic hematopoietic cell transplantation, specifically through the ALLOHA™ Phase 1 heme trial [3] - The company is expanding its ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets associated with multiple HLA types, to provide customized multiplex TCR-T therapies for various cancers, as seen in the PLEXI-T™ Phase 1 solid tumor trial [3] - TScan is currently enrolling patients in both clinical programs [3] Group 2: Upcoming Events - TScan will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 1:10 p.m. Eastern Time [1] - A webcast of the presentation will be available on the company's website, with an archived replay accessible for 90 days post-event [2]

Core Viewpoint - TScan Therapeutics, Inc. is participating in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, focusing on its T cell receptor-engineered T cell therapies for cancer treatment [1]. Company Overview - TScan Therapeutics is a clinical-stage biotechnology company dedicated to developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed for patients with hematologic malignancies, specifically to prevent relapse after allogeneic hematopoietic cell transplantation, as part of the ALLOHA™ Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that target diverse antigens and are compatible with multiple HLA types, to create customized multiplex TCR-T therapies for various cancers, including the PLEXI-T Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3]. Event Information - A webcast of the fireside chat will be accessible on the "Events and Presentations" section of TScan's website, with an archived replay available for 90 days post-event [2].